Business

Announcement on Voluntary Disclosure of Wholly-owned Subsidiary Chengdu Shuode Pharmaceutical Passing U.S. FDA On-site Inspection

Announcement on Voluntary Disclosure of Wholly-owned Subsidiary Chengdu Shuode Pharmaceutical Passing U.S. FDA On-site Inspection

articleChengdu Easton Biopharmaceuticals Co., Ltd. Class ANovember 27, 20253/news/announcement-on-voluntary-disclosure-of-wholly-owned-subsidiary-chengdu-shuode-pharmaceutical-passing-us-fda-on-site-inspection
Announcement on Voluntary Disclosure of Wholly-owned Subsidiary Chengdu Shuode Pharmaceutical Passing U.S. FDA On-site Inspection

About this update from Chengdu Easton Biopharmaceuticals Co., Ltd. Class A

Announcement on Voluntary Disclosure of Wholly-owned Subsidiary Chengdu Shuode Pharmaceutical Passing U.S. FDA On-site InspectionThe abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Chengdu Easton Biopharmaceuticals Co., Ltd. Class A